met

Overview

MET, also known as c-Met, is a receptor tyrosine kinase that functions as the cell-surface receptor for hepatocyte growth factor. It is an important regulator of cellular processes such as proliferation, survival, motility, invasion, and tissue remodeling. In cancer biology, MET is widely recognized as a clinically relevant oncogenic signaling node because its activation can promote tumor progression, metastatic behavior, and resistance to therapy.

Aberrant MET signaling can arise through multiple mechanisms, including gene amplification and exon 14 skipping alterations, both of which are used as molecular biomarkers in oncology. MET is therefore not only a biologically important receptor in normal physiology, but also a major therapeutic target in precision oncology, particularly in non-small cell lung cancer and other solid tumors where c-Met-directed strategies are being actively investigated.

Recent Publications Summary

MET has emerged as a significant oncogenic driver and therapeutic target across multiple cancer types. In secondary glioblastoma, the PTPRZ1-MET fusion represents a recurrent oncogenic event associated with significantly worse overall and progression-free survival, and was identified among the most informative molecular biomarkers for distinguishing fusion-positive tumors 42547688Aug. MET amplification has been identified as a molecular co-alteration in esophageal adenocarcinoma, particularly in association with SMARCA2/4-deficiency 42527418Jul. In lung cancer diagnostic specimens, MET exon 14 skipping events have been successfully detected as treatment-relevant molecular alterations through RNA-based profiling of small bronchoscopic tumor samples 42509268Jul.

Multiple therapeutic strategies have been developed to target MET across cancer indications. A phase I study of telisotuzumab adizutecan (Temab-A), a c-Met-targeting antibody-drug conjugate conjugated to a topoisomerase 1 inhibitor payload, evaluated safety and efficacy in patients with advanced solid tumors and metastatic colorectal cancer 42066233May. In pancreatic cancer, inhibition of the ENO1-c-MET interaction through disruption of ENO1 membrane translocation has shown promise for suppressing PI3K/AKT signaling and achieving hypoxia-selective cytotoxic activity 42053225Apr. Dual-targeting approaches have been explored using multivalent aptamer-drug hybrids that simultaneously engage c-Met and CD71 to enhance tumor-specific uptake and enable coordinated delivery of chemotherapeutic and immunostimulatory agents 41973478Apr.

In non-small cell lung cancer, MET has been investigated both as a biomarker for therapeutic selection and as a direct therapeutic target. Machine learning approaches have been developed to reliably distinguish MET-positive from TROP-2-positive NSCLC phenotypes to guide antibody-drug conjugate selection 41945491Apr. Additionally, self-assembling aggregation-induced emission nanoprobes targeting c-Met have demonstrated downregulation of c-Met expression and suppression of downstream signaling cascades including FAK, MAPK, RAF, and STAT, while enabling real-time fluorescence imaging for tumor visualization and localization 41793940Mar.

What Changes, What Holds

1. MET is now implicated in additional tumor-specific biomarkers and prognostic stratification beyond the baseline account
NEW DIRECTION Secondary glioblastoma data extend MET from a general oncogenic signaling node to a more specific fusion-defined biomarker, with the PTPRZ1-MET fusion linked to poorer outcomes and stronger molecular separation of fusion-positive tumors 42547688Aug. The esophageal adenocarcinoma and lung biopsy findings also broaden the clinical map of MET alterations, but they mainly reinforce its established biomarker role rather than overturning it 42527418Jul42509268Jul.

2. MET-targeted therapy is expanding into new delivery formats and combination concepts, but the baseline therapeutic target role still holds
REINFORCES Telisotuzumab adizutecan adds another MET-directed agent to the precision-oncology toolkit, while the ENO1-c-MET and aptamer-drug hybrid studies suggest new ways to exploit MET biology for selective tumor targeting 42066233May42053225Apr41973478Apr. None of this displaces the established view of MET as a therapeutic target; it mainly broadens the kinds of interventions being tested.

3. MET status is becoming more actionable for treatment selection and image-guided targeting in lung cancer
REINFORCES Machine-learning discrimination of MET-positive from TROP-2-positive NSCLC supports the existing precision-oncology use of MET as a biomarker for therapeutic selection, rather than changing what MET is 41945491Apr. The c-Met-targeting nanoprobes likewise fit the established therapeutic-target framework, adding a diagnostic and imaging layer without challenging the baseline account 41793940Mar.

Overview update candidates: PTPRZ1-MET fusion prognostic value; MET amplification in SMARCA2/4-deficient esophageal adenocarcinoma; RNA-based detection of MET exon 14 skipping in small lung samples; MET-targeted antibody-drug conjugate development; ENO1-c-MET interaction as a therapeutic vulnerability; dual-targeting aptamer-drug delivery strategies; MET-based phenotyping to guide ADC choice; c-Met-targeted fluorescence imaging and signaling suppression in NSCLC.